Understanding the impact of multimorbidity, medications and frailty on zoledronic acid efficacy in treating osteoporosis among older adults
The study emphasizes that identifying barriers to treatment success is crucial for optimizing OP management. ZA improves BMD and reduces fractures, even in frail older adults with multimorbidity, supporting its use across diverse patient profiles and stressing the need for personalized treatment strategies.
Authors
- Münevver Özcan (ORCID: https://orcid.org/0000-0001-8593-7115)
- Serdar Ceylan (ORCID: https://orcid.org/0000-0001-5885-4023)
- Burcu Balam Doğu (ORCID: https://orcid.org/0000-0002-4430-6146)
- Berşan Özcan (ORCID: https://orcid.org/0000-0001-9011-5407)
- Merve Güner (ORCID: https://orcid.org/0000-0002-7417-5415)
- Meltem Gulhan Halil (ORCID: https://orcid.org/0000-0001-7597-8140)
- Cafer Balcı (ORCID: https://orcid.org/0000-0002-1478-1106)
- Mustafa Cankurtaran
Institutions
- Hacettepe University (TR)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1002/bcp.70243
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00